Company / SG&A Expense
Arrowhead Pharmaceuticals SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$123.9M
FY2025
5-year range
$52.3M / $123.9M
FY2021-FY2025
Trend
+25.5%
vs FY2024
Sector context
#101 of 213
Health Care
What the data says
At $124M, Arrowhead Pharmaceuticals's sg&a expense ranks #113 of 213 in the Health Care sector. SG&A Expense has increased for 3 consecutive years, from $52M in FY2022 to $124M in FY2025.
Based on SEC 10-K filings.
$124M in FY2025 with a 5-year CAGR of +18.8%.
Increased from $81M to $124M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +33.3%
- 5-Year CAGR
- +18.8%
- 10-Year CAGR
- -
Sector benchmark
#113 of 213 in Health CareTop 53% of 213This company $123.9M Sector average $722.3M
▼
-82.8% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's sg&a expense has grown for 3 consecutive years.
- 5-year CAGR of +18.8%, indicating consistent growth.
- In FY2025, sg&a expense increased 25.5% year-over-year.
- Ranks #101 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $123.9M | +25.5% |
| FY2024 | $98.8M | +22.0% |
| FY2023 | $81.0M | +54.9% |
| FY2022 | $52.3M | -35.4% |
| FY2021 | $81.0M | +54.9% |
| FY2020 | $52.3M | +198.7% |
| FY2019 | $17.5M | -25.8% |
| FY2018 | $23.6M | +197.5% |
| FY2017 | $7.9M | -66.4% |
| FY2016 | $23.6M | +576.3% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026